Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

David A. Bond; Jeffrey M. Switchenko; Diego Villa; Kami Maddocks; Michael Churnetski; Alina S. Gerrie; Subir Goyal; Krithika Shanmugasundaram; Oscar Calzada; Bhaskar C Kolla; Veronika Bachanova; James N. Gerson; Stefan K. Barta; Brian T. Hill; Yazeed Sawalha; Peter Martin; Edward Maldonado; Max Gordon; Alexey V. Danilov; Natalie S. Grover; Stephanie Mathews; Madelyn Burkart; Reem Karmali; Nilanjan Ghosh; Steven I. Park; Narendranath Epperla; Talha Badar; Jin Guo; Mehdi Hamadani; Timothy S. Fenske; Mary Kate Malecek; Brad S. Kahl; Christopher R. Flowers; Kristie A. Blum; Jonathon B. Cohen

doi:10.1182/bloodadvances.2021004765

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

David A. Bond, Jeffrey M. Switchenko, Diego Villa, Kami Maddocks, Michael Churnetski, Alina S. Gerrie, Subir Goyal, Krithika Shanmugasundaram, Oscar Calzada, Bhaskar C Kolla, Veronika Bachanova, James N. Gerson, Stefan K. Barta, Brian T. Hill, Yazeed Sawalha, Peter Martin, Edward Maldonado, Max Gordon, Alexey V. Danilov, Natalie S. GroverStephanie Mathews, Madelyn Burkart, Reem Karmali, Nilanjan Ghosh, Steven I. Park, Narendranath Epperla, Talha Badar, Jin Guo, Mehdi Hamadani, Timothy S. Fenske, Mary Kate Malecek, Brad S. Kahl, Christopher R. Flowers, Kristie A. Blum, Jonathon B. Cohen

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) afterfirst-line therapy among455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive diseaseduringinduction orPODwithin6monthsof diagnosis (n565;14%);POD6-24, definedasPODbetween 6and24months after diagnosis (n5153; 34%);andPOD.24, defined asPOD.24monthsafterdiagnosis(n5237;53%).ThemedianoverallsurvivalfromPOD(OS2) was 1.3 years (95%confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95%CI, 6.2-NR) for those withPOD.24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until PODwasreplicated inanindependent cohort of 245 patients with relapsedMCL,withmedian OS2 of 0.3 years (95%CI, 0.1-0.5) for PRF/POD6, 0.8 years (95%CI, 0.6-0.9) for POD6-24, and 2.4 years (95%CI 2.1-2.7) for POD.24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.

Original language	English (US)
Pages (from-to)	5179-5189
Number of pages	11
Journal	Blood Advances
Volume	5
DOIs	https://doi.org/10.1182/bloodadvances.2021004765
State	Published - Dec 14 2021

Bibliographical note

Publisher Copyright:
© 2021 by The American Society of Hematology.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1182/bloodadvances.2021004765

Find It

Find It at U of M Libraries

Cite this

Bond, D. A., Switchenko, J. M., Villa, D., Maddocks, K., Churnetski, M., Gerrie, A. S., Goyal, S., Shanmugasundaram, K., Calzada, O., Kolla, B. C., Bachanova, V., Gerson, J. N., Barta, S. K., Hill, B. T., Sawalha, Y., Martin, P., Maldonado, E., Gordon, M., Danilov, A. V., ... Cohen, J. B. (2021). Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Advances, 5, 5179-5189. https://doi.org/10.1182/bloodadvances.2021004765

Bond, DA, Switchenko, JM, Villa, D, Maddocks, K, Churnetski, M, Gerrie, AS, Goyal, S, Shanmugasundaram, K, Calzada, O, Kolla, BC, Bachanova, V, Gerson, JN, Barta, SK, Hill, BT, Sawalha, Y, Martin, P, Maldonado, E, Gordon, M, Danilov, AV, Grover, NS, Mathews, S, Burkart, M, Karmali, R, Ghosh, N, Park, SI, Epperla, N, Badar, T, Guo, J, Hamadani, M, Fenske, TS, Malecek, MK, Kahl, BS, Flowers, CR, Blum, KA & Cohen, JB 2021, 'Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy', Blood Advances, vol. 5, pp. 5179-5189. https://doi.org/10.1182/bloodadvances.2021004765

@article{27d1cdd255624c1ab724a9d10162b7ab,

title = "Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy",

abstract = "Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) afterfirst-line therapy among455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive diseaseduringinduction orPODwithin6monthsof diagnosis (n565;14%);POD6-24, definedasPODbetween 6and24months after diagnosis (n5153; 34%);andPOD.24, defined asPOD.24monthsafterdiagnosis(n5237;53%).ThemedianoverallsurvivalfromPOD(OS2) was 1.3 years (95%confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95%CI, 6.2-NR) for those withPOD.24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until PODwasreplicated inanindependent cohort of 245 patients with relapsedMCL,withmedian OS2 of 0.3 years (95%CI, 0.1-0.5) for PRF/POD6, 0.8 years (95%CI, 0.6-0.9) for POD6-24, and 2.4 years (95%CI 2.1-2.7) for POD.24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.",

author = "Bond, {David A.} and Switchenko, {Jeffrey M.} and Diego Villa and Kami Maddocks and Michael Churnetski and Gerrie, {Alina S.} and Subir Goyal and Krithika Shanmugasundaram and Oscar Calzada and Kolla, {Bhaskar C} and Veronika Bachanova and Gerson, {James N.} and Barta, {Stefan K.} and Hill, {Brian T.} and Yazeed Sawalha and Peter Martin and Edward Maldonado and Max Gordon and Danilov, {Alexey V.} and Grover, {Natalie S.} and Stephanie Mathews and Madelyn Burkart and Reem Karmali and Nilanjan Ghosh and Park, {Steven I.} and Narendranath Epperla and Talha Badar and Jin Guo and Mehdi Hamadani and Fenske, {Timothy S.} and Malecek, {Mary Kate} and Kahl, {Brad S.} and Flowers, {Christopher R.} and Blum, {Kristie A.} and Cohen, {Jonathon B.}",

note = "Publisher Copyright: {\textcopyright} 2021 by The American Society of Hematology.",

year = "2021",

month = dec,

day = "14",

doi = "10.1182/bloodadvances.2021004765",

language = "English (US)",

volume = "5",

pages = "5179--5189",

journal = "Blood Advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

}

TY - JOUR

T1 - Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

AU - Bond, David A.

AU - Switchenko, Jeffrey M.

AU - Villa, Diego

AU - Maddocks, Kami

AU - Churnetski, Michael

AU - Gerrie, Alina S.

AU - Goyal, Subir

AU - Shanmugasundaram, Krithika

AU - Calzada, Oscar

AU - Kolla, Bhaskar C

AU - Bachanova, Veronika

AU - Gerson, James N.

AU - Barta, Stefan K.

AU - Hill, Brian T.

AU - Sawalha, Yazeed

AU - Martin, Peter

AU - Maldonado, Edward

AU - Gordon, Max

AU - Danilov, Alexey V.

AU - Grover, Natalie S.

AU - Mathews, Stephanie

AU - Burkart, Madelyn

AU - Karmali, Reem

AU - Ghosh, Nilanjan

AU - Park, Steven I.

AU - Epperla, Narendranath

AU - Badar, Talha

AU - Guo, Jin

AU - Hamadani, Mehdi

AU - Fenske, Timothy S.

AU - Malecek, Mary Kate

AU - Kahl, Brad S.

AU - Flowers, Christopher R.

AU - Blum, Kristie A.

AU - Cohen, Jonathon B.

PY - 2021/12/14

Y1 - 2021/12/14

N2 - Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) afterfirst-line therapy among455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive diseaseduringinduction orPODwithin6monthsof diagnosis (n565;14%);POD6-24, definedasPODbetween 6and24months after diagnosis (n5153; 34%);andPOD.24, defined asPOD.24monthsafterdiagnosis(n5237;53%).ThemedianoverallsurvivalfromPOD(OS2) was 1.3 years (95%confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95%CI, 6.2-NR) for those withPOD.24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until PODwasreplicated inanindependent cohort of 245 patients with relapsedMCL,withmedian OS2 of 0.3 years (95%CI, 0.1-0.5) for PRF/POD6, 0.8 years (95%CI, 0.6-0.9) for POD6-24, and 2.4 years (95%CI 2.1-2.7) for POD.24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.

AB - Although an expanding array of effective treatments has resulted in recent improvement in survival of patients with mantle cell lymphoma (MCL), outcomes remain heterogeneous, and identification of prognostic factors remains a priority. We assessed the prognostic impact of time to progression of disease (POD) afterfirst-line therapy among455 patients with relapsed MCL. Patients were categorized by duration of first remission as PRF/POD6, defined as progressive diseaseduringinduction orPODwithin6monthsof diagnosis (n565;14%);POD6-24, definedasPODbetween 6and24months after diagnosis (n5153; 34%);andPOD.24, defined asPOD.24monthsafterdiagnosis(n5237;53%).ThemedianoverallsurvivalfromPOD(OS2) was 1.3 years (95%confidence interval [CI], 0.9-2.4) for patients with PRF/POD6, 3 years (95% CI, 2-6.8) for those with POD6-24, and 8 years (95%CI, 6.2-NR) for those withPOD.24. Median OS2 was inferior in patients with early POD (defined as PRF/POD6 or POD6-24) after both intensive and less intensive frontline treatment. The prognostic performance of time until PODwasreplicated inanindependent cohort of 245 patients with relapsedMCL,withmedian OS2 of 0.3 years (95%CI, 0.1-0.5) for PRF/POD6, 0.8 years (95%CI, 0.6-0.9) for POD6-24, and 2.4 years (95%CI 2.1-2.7) for POD.24. Early POD is associated with inferior OS2 in patients with relapsed MCL, identifying a high-risk population for future prospective studies.

UR - http://www.scopus.com/inward/record.url?scp=85120335416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85120335416&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2021004765

DO - 10.1182/bloodadvances.2021004765

M3 - Article

C2 - 34516611

AN - SCOPUS:85120335416

SN - 2473-9529

VL - 5

SP - 5179

EP - 5189

JO - Blood Advances

JF - Blood Advances

ER -

Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this